West Nile - Pipeline Insight, 2025

This “West Nile - Pipeline Insight, 2025,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in West Nile pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

West Nile Understanding

West Nile: Overview

The West Nile virus is an enveloped, single-stranded RNA arbovirus that can cause disease in humans. These range from the asymptomatic infected patient to fever and malaise to florid neurological deficits secondary to encephalitis and neuroinvasive disease. It is known to cause disease in humans with a wide array of presentations. These range from the asymptomatic infected patient to fever and malaise to florid neurological deficits secondary to encephalitis. However, most people infected with West Nile virus are asymptomatic. Approximately 1 in 4 patients experience fever with symptoms of a viral syndrome, while around 1 in 200 develops neuroinvasive disease. The West Nile virus infects humans following a mosquito bite. The Culex species of mosquito is the most common vector. Besides humans, the West Nile virus can infect birds, horses, dogs, and many other mammals. Wild birds may be the optimal hosts for harboring and enabling amplification of the virus. Humans are considered accidental dead-end hosts due to the low and transient viral levels in the bloodstream. Additional and rare means of transmission include infected donor blood, organs, breast milk, or transplacental infection.

Routine labs may reveal leukocytosis and other non-specific findings secondary to the viral infection. The diagnosis is via serologic detection of West Nile virus using an enzyme-linked immunosorbent assay (ELISA) for the IgM antibody in blood or CSF samples. A plaque reduction neutralization test (PRNT) can distinguish serologic cross-reactions. Treatment of West Nile virus is primarily supportive care. Researchers have tried several agents including interferon, ribavirin, and intravenous immunoglobulin. No clear efficacy data exists as only one controlled study has been performed to date.

'West Nile - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the West Nile pipeline landscape is provided which includes the disease overview and West Nile treatment guidelines. The assessment part of the report embraces, in depth West Nile commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, West Nile collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

In May 2020, Orgenesis launched its new cell-based vaccine platform targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, as well as other viral diseases such as Zika, West Nile Virus, Yellow Fever, Dengue Fever, MERS, HCV and Cytomegalovirus infection (CMV).

West Nile Emerging Drugs Chapters

This segment of the West Nile report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

West Nile Emerging Drugs

West Nile virus vaccine: Najit technologies

Najit technologies has developed a second-generation WNV vaccine that has shown further enhanced immune responses that are up to 130-fold higher than previously observed with the original HydroVax technology, and the company has recently completed cGMP manufacturing in preparation for Phase I clinical studies. This vaccine has the potential to be used by a broad and immunologically diverse population without the risk of rare, lethal infection associated with certain live viral vaccines.

Research programme infectious diseases therapeutics: Plex Pharmaceuticals

Plex pharmaceuticals has a development program for Dengue, West Nile and Zika antiviral drugs which has also received support from the NIH and has worked on a novel brain-penetrant heat shock protein 90 (HSP90) inhibitor for Glioblastoma.

West Nile: Therapeutic Assessment

This segment of the report provides insights about the different West Nile drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in West Nile

There are approx. 7+ key companies which are developing the therapies for West Nile. The companies which have their West Nile drug candidates in the most advanced stage, i.e. phase I include, Najit Technologies.

Phases

The report covers around 7+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

West Nile pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

West Nile: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses West Nile therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging West Nile drugs.

West Nile Report Insights

• West Nile Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

West Nile Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing West Nile drugs?
• How many West Nile drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of West Nile?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the West Nile therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for West Nile and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Najit Technologies
• Ennaid Therapeutics
• Hawaii Biotech
• Plex Pharmaceuticals
• Protinhi Therapeutics
• Innovation Pharmaceuticals
• NanoViricides
• Orgenesis

Key Products

• West Nile virus vaccine
• ETxR12
• HBV 002
• Research programme infectious diseases therapeutics
• Research programme: Flavivirus infections therapeutics
• Brilacidin
• Research programme: antiviral vaccines

This product will be delivered within 2 business days.